First Randomized, Placebo-Controlled Trial of Inhaled rhGM-CSF in aPAP Patients
Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune pulmonary alveolar proteinosis (aPAP).